for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Zynerba Pharmaceuticals Inc

ZYNE.OQ

Latest Trade

4.57USD

Change

-0.07(-1.51%)

Volume

29,463

Today's Range

4.53

 - 

4.64

52 Week Range

3.15

 - 

9.00

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
4.64
Open
4.63
Volume
29,463
3M AVG Volume
27.62
Today's High
4.64
Today's Low
4.53
52 Week High
9.00
52 Week Low
3.15
Shares Out (MIL)
41.25
Market Cap (MIL)
198.42
Forward P/E
-4.76
Dividend (Yield %)
--

Next Event

Zynerba Pharmaceuticals Inc Annual Shareholders Meeting

Latest Developments

More

Zynerba Pharmaceuticals Reports Q1 Loss Per Share Of $0.20

Zynerba Pharma Reports Q4 Loss Per Share Of $0.33

Zynerba Pharmaceuticals Provides Regulatory Update On Zygel In Fragile X Syndrome

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Zynerba Pharmaceuticals Inc

Zynerba Pharmaceuticals, Inc. is a specialty pharmaceutical company. The Company is engaged in developing and commercializing transdermal synthetic cannabinoid treatments for patients with high unmet needs. Its development pipeline includes two product candidates: ZYN002 and ZYN001. ZYN002 is a synthetic cannabidiol (CBD), which is a non-psychoactive cannabinoid, formulated as a patent-protected permeation-enhanced gel for transdermal delivery through the skin and into the circulatory system. ZYN002 is in Phase II clinical development in patients with refractory epilepsy, in patients with osteoarthritis of the knee, as well as in patients with Fragile X syndrome. ZYN001 is a pro-drug of tetrahydrocannabinol (THC) that enables transdermal delivery through the skin and into the circulatory system through a patch. ZYN001 is targeting two pain indications, fibromyalgia and peripheral neuropathic pain.

Industry

Biotechnology & Drugs

Contact Info

80 W. Lancaster Avenue, Suite 300

DEVON, PA

19333

United States

+1.484.5817505

http://zynerba.com/

Executive Leadership

Armando Anido

Chairman of the Board, Chief Executive Officer

Terri B. Sebree

President

James E. Fickenscher

Chief Financial Officer, Vice President - Corporate Development

Suzanne M. Hanlon

Vice President, General Counsel, Secretary

Brian Rosenberger

Vice President - Commercial and Business Development

Key Stats

2.00 mean rating - 7 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2018

0.0K

2019

0.0K

2020

0.0K

2021(E)

0.0K
EPS (USD)

2018

-2.610

2019

-1.500

2020

-1.900

2021(E)

-1.010
Price To Earnings (TTM)
--
Price To Sales (TTM)
--
Price To Book (MRQ)
2.07
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
0.00
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
-57.82
Return on Equity (TTM)
-50.69

Latest News

Latest News

Zynerba's cannabis-based drug for rare genetic disorder fails study

Zynerba Pharmaceuticals Inc said on Tuesday its experimental cannabis-based gel Zygel was not statistically significant in improving aberrant behavior when compared to a placebo in patients with a neurological disorder called Fragile X syndrome.

BRIEF-Zynerba Pharmaceuticals Announces Top Line Results From Pivotal Connect-FX Trial Of Zygel

* ZYNERBA PHARMACEUTICALS ANNOUNCES TOP LINE RESULTS FROM PIVOTAL CONNECT-FX TRIAL OF ZYGEL™ (CBD GEL) IN FRAGILE X SYNDROME

Zynerba's cannabis-based drug for rare genetic disorder fails study

Zynerba Pharmaceuticals Inc said on Tuesday its experimental cannabinoid gel, Zygel, did not meet main and key secondary goals of a pivotal trial in patients with a neurological disorder called Fragile X syndrome.

BRIEF-Zynerba Says Bright Trial Achieved Clinically Meaningful Improvements From Baseline

* ZYNERBA PHARMACEUTICALS ANNOUNCES POSITIVE TOP LINE RESULTS FROM EXPLORATORY OPEN LABEL PHASE 2 BRIGHT TRIAL OF ZYGEL IN AUTISM SPECTRUM DISORDER

BRIEF-Zynerba Pharmaceuticals Announces New Two-Year Data From Open Label Extension Of The Phase 2 Fab-C Trial In Patients With Fragile X

* ZYNERBA PHARMACEUTICALS ANNOUNCES NEW TWO-YEAR DATA FROM OPEN LABEL EXTENSION OF THE PHASE 2 FAB-C TRIAL IN PATIENTS WITH FRAGILE X AT 2020 AMERICAN ACADEMY OF NEUROLOGY (AAN) SCIENCE HIGHLIGHTS VIRTUAL SESSION

BRIEF-Zynerba Pharmaceuticals Reports First Quarter 2020 Results

* ZYNERBA PHARMACEUTICALS REPORTS FIRST QUARTER 2020 FINANCIAL RESULTS AND OPERATIONAL HIGHLIGHTS

BRIEF-Zynerba Pharmaceuticals Announces The Completion Of Enrollment In The Pivotal Connect-FX Trial Of Zygel In Fragile X Syndrome

* ZYNERBA PHARMACEUTICALS ANNOUNCES THE COMPLETION OF ENROLLMENT IN THE PIVOTAL CONNECT-FX TRIAL OF ZYGEL™ IN FRAGILE X SYNDROME

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up